MIRA
INFORM REPORT
|
Report Date : |
26.05.2011 |
IDENTIFICATION DETAILS
|
Name : |
GUYTON
PHARMACEUTICALS |
|
|
|
|
Registered Office : |
25.5 K.M., Raiwind Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
2004 |
|
|
|
|
Legal Form : |
Partnership |
|
|
|
|
Line of Business : |
Manufacture
& Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
Pakistan |
B2 |
B2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Business Name
GUYTON PHARMACEUTICALS
Full Address
|
Registered
Address & Factory |
|
25.5 K.M., Raiwind Road, Lahore, Pakistan |
|
Tel # |
92 (42) 35321070, 35320940, +923018471985 |
|
Fax # |
92 (42) 35320940 |
|
Email |
Short Description Of Business
|
Nature of Business |
Manufacture
& Marketing of Pharmaceutical Products |
|
Year Established |
2004 |
Branches
|
In Karachi at present |
Legal Status
|
Subject Company was established as a Partnership business in 2004 |
Details of Managing Partner /
Partners
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Bilal Khurshid Siddiqui Mrs. Sidra Zafar |
Pakistani Pakistani |
25.5 K.M.,
Raiwind Road, Lahore 25.5 K.M.,
Raiwind Road, Lahore |
Business Business |
Managing Partner Partner |
Associates
A. Subsidiary
None
B. Associated
Companies
- Do -
Products
(1) Subject
Company is engaged in manufacture & marketing of Pharmaceutical Products.
(2)
It purchases raw material against D/A, D/P basis.
(3) Its mainly import from China, India, Taiwan,
Korea, Germany & Italy.
(3) Its’ major
customers are Distributors, Traders, Pharmacies & Hospitals.
(4) Subject
operates from caption leased factory premises of area measuring 3,000 Sq.Yard which is situated at
industrial area.
(5)
Subject employs about 70
persons in its set up.
Annual Sales Volume
|
Year |
In Pak Rupees
|
|
2009 |
50,000,000/- (Estimated) |
Capacity & Production
|
The capacity and
production of the company’s plant is indeterminable as it is multi- product
and involves various processes of manufacture. |
Trade Suppliers (Foreign)
(1) ROQUETTE
INTERNATIONAL, FRANCE.
(2) NORTH CHINA
PHARMACEUTICAL GROUP, CHINA.
Bankers
(1)
Habib Bank Limited, Pakistan.
(2) Bank Alfalah
Limited, Pakistan.
(3) MCB Bank Limited,
Pakistan.
(4) United Bank
Limited, Pakistan.
Memberships
·
Lahore Chamber of Commerce & Industry.(LCCI)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 85.70 |
|
UK Pound |
1 |
Rs. 138.40 |
|
Euro |
1 |
Rs. 120.40 |
Comments
Subject Company was established in 2004 and
is engaged in manufacture & marketing of Pharmaceutical Products. Trade
relations are reported as fair. Subject can be considered for normal business
dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.38 |
|
|
1 |
Rs.73.31 |
|
Euro |
1 |
Rs.63.70 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.